Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9496 in advanced breast cancer
NCT02248090Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of AZD9496 in breast cancer, sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Started Oct 2014; status: completed.
02
Drugs
AZD9496
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02248090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248090.